An MRI can often tell whether a cyst is cancerous, but not always. Benign simple cysts contain fluid that looks near-black on T2-weighted images and shows no enhancement after contrast, while malignant cystic masses usually show thick irregular walls, solid enhancing nodules, or restricted diffusion. When those features are absent, MRI is highly reassuring; when they are present, MRI flags risk but cannot confirm cancer without pathology.
A cyst is a fluid-filled sac, and most are harmless. The clinical question is not really "is this a cyst" but "is there anything solid, growing, or enhancing hiding in or around it." MRI answers that question with tissue contrast and contrast-agent behavior that ultrasound and CT cannot fully match. This explainer covers the physics behind those signals, the numbers that separate reassuring from suspicious, the edge cases that fool radiologists, and what to do with a report in hand.
How MRI separates fluid from solid tissue
MRI signal comes from hydrogen protons in water and fat, manipulated by magnetic fields and radio waves. The two sequences that matter most for cysts are T1-weighted and T2-weighted images, which differ in how quickly tissues recover and decay after excitation. Simple fluid has a long T2 relaxation time, so it stays bright on T2 and dark on T1. That single physical fact explains most of cyst interpretation.
Contrast agents add a second layer. Gadolinium shortens T1 relaxation, so tissue that takes up contrast brightens on post-contrast T1 images. A simple cyst has no blood supply, so it does not enhance. A cancerous cystic mass has neovascularity in its walls and septa, so it does. Enhancement is therefore a perfusion test, not a shape test.
Diffusion-weighted imaging (DWI) adds a third layer. DWI measures how freely water molecules move; densely packed tumor cells restrict that motion, producing high signal on high-b-value images and low values on the apparent diffusion coefficient (ADC) map. A simple cyst restricts diffusion only trivially, because its water is free. A cystic tumor with cellular solid components restricts it. Each sequence interrogates a different property, which is why protocols combine them.
What the numbers mean: enhancement, ADC, and size thresholds
Radiologists do not eyeball enhancement; they measure it. A commonly applied threshold for "true enhancement" on MRI is a signal increase of roughly 20 percent or more between pre- and post-contrast images, measured on subtraction images to remove native T1 brightness. Below that, apparent brightening often reflects proteinaceous or hemorrhagic fluid rather than blood flow.
DWI thresholds are scanner-dependent and should not be read as universal constants. As a general orientation, ADC values below roughly 1.0 to 1.2 × 10⁻³ mm²/s in a solid component raise concern for cellular tumor, while simple cyst fluid typically sits far above that range. Because vendor calibration varies, radiologists interpret ADC against internal reference tissue rather than a fixed cutoff. Treat any single number as supportive, not diagnostic.
Size and growth matter as much as signal. Simple cysts generally measure under 3 cm, have imperceptible walls, and show no septa or calcification. A wall thickness above roughly 2 to 3 mm, or a solid nodule of any size, shifts the lesion out of the "simple" category. Growth of a solid component between exams is among the most reliable malignancy signs available on imaging.
Thresholds must be reconciled rather than stacked. A 22 percent enhancement with an ADC of 1.4 and a 2 mm wall is not the same lesion as 25 percent enhancement with an ADC of 0.9 and a 6 mm nodule. The first combination is usually benign; the second usually warrants tissue. The radiologist integrates enhancement, diffusion, morphology, and growth into one impression, which is why reading a single metric out of context misleads.
| Feature | Typical simple cyst | Suspicious cystic mass | What it reflects |
|---|---|---|---|
| T2 signal | Uniformly very bright | Mixed, dark solid parts | Free water vs cells |
| T1 signal | Dark | Variable, often dark | Protein, blood, melanin |
| Post-contrast | No enhancement | Wall or nodule enhancement | Blood supply |
| Wall and septa | Imperceptible, none | Thick, irregular, nodular | Architectural distortion |
| ADC value | High (near fluid) | Low in solid parts | Cell density |
| Growth | Stable over years | Solid parts enlarge | Proliferation |
Where MRI can be fooled: cysts that mimic cancer and cancer that mimics cysts
Complex benign cysts are the classic trap. A hemorrhagic cyst contains blood products that are bright on T1 and can look enhancing on subtraction if technique is imperfect, mimicking a solid tumor. Protein-rich cyst fluid behaves the same way. Endometriomas, which contain old blood, are a well-known example of a benign lesion that looks alarming on T1.
A professional caveat worth knowing: an MRI read without the patient's history, prior imaging, and ultrasound is a compromised study. The same lesion can be a hemorrhagic cyst in one patient and a cystic neoplasm in another. Radiologists routinely downgrade or upgrade an impression after comparing with ultrasound, which visualizes septa and calcifications differently.
Cancer can mimic a cyst in the other direction. Some malignant tumors are almost entirely necrotic or mucinous, so their centers look like fluid and only a thin rim enhances. If that rim is overlooked or the solid component is small, a tumor can be misread as a complicated cyst. This is why any enhancing septation, however thin, deserves attention.
Counterintuitive detail: the absence of enhancement is more informative than its presence. Small amounts of apparent enhancement are common artifacts and benign protein; a truly non-enhancing, thin-walled, T2-bright lesion is very rarely malignant. Conversely, a small enhancing nodule carries disproportionate weight. The diagnostic logic is asymmetric.
Practical actions after an MRI report
A report that says "simple cyst" with no enhancement, imperceptible walls, and high ADC needs no biopsy. That impression is highly specific for a benign lesion in most organs. The action is usually no action beyond routine follow-up appropriate to the organ and the patient's history.
Red flag: a solid, enhancing nodule within or on the wall of the cyst. Red flag: wall or septal thickness above roughly 3 mm, especially irregular. Red flag: low ADC in a solid component, roughly below 1.0 to 1.2 × 10⁻³ mm²/s. Red flag: interval growth of a solid component on serial imaging. Red flag: new symptoms such as pain, bleeding, or obstruction near the lesion.
When these appear, the next step is usually referral to a specialist and often biopsy or surgical excision, because imaging can only estimate risk. A radiologist's "suspicious" impression is a probability statement, not a diagnosis. The only way to confirm cancer is pathologic examination of tissue.
When a report is ambiguous, ask three questions. Which sequence showed the finding, and was enhancement measured on subtraction images? What is the wall thickness and the ADC of any solid part? What did prior imaging show? Those three answers resolve most uncertainty. If the report cannot answer them, a second read at a center with organ-specific MRI expertise is reasonable.
Timeline: from scan to certainty
| Stage | What happens | Typical timing |
|---|---|---|
| MRI acquisition | Multi-sequence protocol, often with contrast | 30 to 60 minutes |
| Radiologist interpretation | Comparison with priors and ultrasound | Same day to a few days |
| Report and communication | Impression categorized as simple, indeterminate, suspicious | Within days |
| Specialist review | Surgery, urology, gynecology, or oncology input | Days to weeks |
| Biopsy or excision | Tissue sampling or removal | Weeks |
| Pathology | Histologic diagnosis | Days after sampling |
| Follow-up imaging | Surveillance of stable indeterminate lesions | Months to years |
What MRI cannot tell you, and why that limit is stable
MRI cannot confirm cancer. It estimates risk from tissue properties: fluid behavior, enhancement, cellularity, morphology, and change over time. Those properties are stable physics, which is why the core logic of cyst interpretation does not change with new scanner models. What changes is resolution and protocol quality, not the underlying principles.
No modality replaces pathology for a definitive answer. Even the most suspicious MRI impression is followed by tissue diagnosis when management depends on it. The practical value of MRI is triage: it reliably sorts cysts into reassuring, indeterminate, and suspicious groups, sparing most benign lesions from procedures while flagging the ones that need tissue.
The referenced thresholds and contrast mechanisms are widely established radiology principles; specific cutoff values vary by scanner, protocol, and organ, and should be interpreted by the reading radiologist rather than applied as universal rules.